Recruitment of cancer patients by LCRN - PowerPoint Presentation

Slide1

Recruitment of cancer patients by LCRN Subspecialty: Haem Onc & Lymphoma Recruits per 100,000 Population

1Slide2
Slide3
Slide4
Slide5
Slide6

MYELOMA 1st line

MYELOMA XI

Randomised comparisons of thalidomide, lenalidomide, bortezomib, carfilzomib combinations and maintenance lenalidomide

UHB/NBT/C+G

Cardamon

Carfilzomib/Cyclo/Dex with maintenance carfilzomib in untreated ASCT-eligible patients

In set-up RUH

TEAMM

Randomized, double-blind, phase III trial of levofloxacin vs placebo in newly diagnosed MM requiring therapy

RUH/NBT/Swindon/C+G

Millennium

Ixazomib maintenance vs placebo after induction therapy if not having ASCT.

UHB In set-up RUH/NBT

2

nd

line

MUK5

CCD (cyclo/carfilz/dex) vs CVD (cyclo/bortezomib/dex) as second line therapy

UHB- JB

MUK8

Relapsed disease randomised trial

UHB-JB in set-up

Amyloid

Prothena

Mab against amyloid protein

UHB-JB/JG in set-up

LYMPHOMA

1

st

line

MCL biobank

All patients newly diagnosed with mantle cell lymphoma, whether requiring therapy or not

UHB/NBT/C+G/Taunton

ENRICH

Older MCL R-ibrutinib vs R-chemo (CHOP or bendamustine at investigator’s discretion)

EOI C+G/UHB

Chemo-T

CHOPx6 vs GEM-P x4

Taunton /C+G/Yeovil

ReModL-B

Adding bortezomib to R-CHOP on basis of GEP – closing June 2015

C+G/RUH/Swindon

R2W

FCR vs bortezomib/cyclo/ritux (BCR) in previously untreated Waldenstroms

RUH/Taunton

MAPLE

FL 3b/DLBCL – observational study of molecular profiling ? new agents in future

RUH/Swindon

EBV

Observational study in EBV assoc T-cell/NK malignancies.

Taunton

PACIFICO

R-CVP vs FCR lite in older patients with untreated follicular NHL

Weston/RUH

NCRN 3171

Double-blind RCT ritux vs biosimilar x4 in untreated, low tumour burden FL.

RUH

INCA

Newly diagnosed DLBCL with cardiac contra-indications to anthracycline – IO-R-CVP vs Gem-R-CVP

UHB /NBT/RUH

NHL TYA

Registry study for all NHL diagnosed age 15-29

UHB in set up LL

Relapsed/refractory

LEGEND

Lenalidomide/gemcitabine/methylpred (L-R-Gem) vs R-GEM-P in relapsed/refractory DLBCL

Taunton – S Bolam

ARROVEN

Relapsed/refractory HL or ALCL – observational study

C+G

LYMRIT-37-01

Phase II – Betalutin (CD37 antibody with radio-isotope) in relapsed FL I-IIIA, marginal zone, SLL, lymphoplasmacytic, mantle cell lymphoma

UHB – Matt Beasley

LYMRIT

Betalutin in r/r FL

UHB in set-up MB

LYMRIT

Betalutin in r/r/ DLBCL

UHB in set-up MB

SADAR

Selinexor in r/r DLBCL

C+G in set up

CLL

1

st

line

FLAIR

FCR vs R-ibrutinib aged 18-75. >20% p53 deletion by FISH excluded.

UHB/NBT/RUH/Taunton, in set-up C+G

Rialto

In less fit patients Ofatumumab/chlorambucil vs Ofatumumab/bendamustine, plus idelalisib vs placebo

Weston/RUH/Swindon/C+G/Yeovil

GALACTIC

GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL

NBT- Sophie

Otton

, in set-up RUH/C+GSlide7

ALL 1st line UKALL2011

Newly diagnosed, Ph-ve ALL patients, aged less than 25

UHB – John Moppett

RUH in set-up

UKALL14

Newly diagnosed ALL patients, aged 25-65 (Ph+ve patients aged 19-65 are eligible)

UHB – David Marks

RUH/C+G/Taunton

UKALL60+

Phase 2 study in newly diagnosed patients with ALL aged over 60 (or over 55 unsuitable for UKALL14)

UHB – DM/Taunton

In set-up C+G

GLOBALL

Coagulation in newly diagnosed ALL - observational

UHB - CB

2

nd

line

T

OWER

Blinatumomab vs standard care in relapsed/refractory Ph- ALL

UHB – DM

Leukaemia/MDS

WT1

Phase 1/2 WT1 TCR gene therapy. AMLnot for allograft - 2

nd

CR, or 1

st

CR in poor risk or >60; CML resistant to imatinib+2

nd

gen TKI not suitable for SCT

UHB – DM

AML

1

st

line

AML 18

AML/RAEB-2 patients, usually aged over 60, fit for intensive therapy

UHB-PM / C+G, In set-up RUH

AML 19

Newly diagnosed patients with AML, aged under 60

UHB in set-up –PM/ RUH/Taunton/C+G

AML LI-1

Newly diagnosed AML (not APL) or RAEB-2, not suitable for intensive therapy, aged over 60.

UHB – PM

Swindon/C+G/Yeovil

Cytarabine sens

Observational study in all AML patients – blood or marrow samples required

UHB – PM

APL coag

Pilot study – understanding and managing the coagulopathy in APL

Taunton

WT-1

Gene therapy study for high risk MDS/AML

UHB-RP in set up

2

nd

line

AMBIT

AC-220 vs standard care in patients with first relapse of FLT3-ITD positive AML

UHB – Priyanka Mehta

CML

SPIRIT 3

On hold centrally

UK-TARGET-CML

EOI C+G

Transplant

UK-POSTAGE

Prospective study of 2

nd

line therapy for acute GVHD, can have had up to 3 weeks steroid therapy for GVHD

UHB –JG

FIGARO

AML/MDS patients having RIC allo SCT – randomised comparison of FLAMSA-BU vs standard conditioning

UHB – RP

Pro T4

Prophylactic transfer CD4+ lymphocytes in patients undergoing FMC sib allo for haematological cancer (2:1 randomisation DLI vs none)

UHB – SR

UK haplo

Haplo SCT (RIC or myeloablative)

UHB – RP

Aztec

Azacytidine for GVHD

UHB – RP in set-up

MDS

MDS Bio

Observational study in all patients with MDS/CMML – please consider when performing a marrow biopsy where MDS is a possible diagnosis

UHB – PM, NBT – AW, C+G

Aza-MDS

Azacitidine vs supportive care in patients with transfusion dependent MDS with PLT <75, IPSS score 0-1.0

UHB – Priyanka Mehta

HR-Elastic

REDDS

De-iron

Phase 2 study of deferasirox at early iron loading in transfusion-dependent MDS

Taunton

MDS-010

Non-interventional study of Low/INT-1 MDS patients, transfusion dependent, with isolated 5q-

In set-up RUHSlide8

MPN 

  Majic

Ruxolitinib vs best care with PV + high risk feature(>60, previous thrombosis, splenomegaly, PLT >1000, DM /↑bp) resistant to/intolerant of OHurea

RUH/Swindon/Taunton/C+G

MPD-RC114

Ruxolitinib in myelofibrosis pre allograft

UHB-JG in set-up

Other

PNH registry

Patients of any age with a diagnosis of PNH, or a detected PNH clone.

UHB – Priyanka Mehta

Brightlight

Young people aged 13-24 with cancer diagnsosi, recruited within 4 months of diagnosis

RUH

InCite

Case-control study of IC haemorrhage in thrombocytopenic haematology patients

RUH

Zoster002

VZV vaccine therapy in ASCT patients

Swindon

Zoster039

VZV vaccine in haematology patients

Swindon

TREATT

Trial to Evaluate Antifibrinolytic Therapy in Thrombocytopenia

UHB – Andrew Mumford

Non-cancer

ITP registry

All patients diagnosed at any time, need consent and 4 extra bottles EDTA blood, PLT <100

UHB – CB/RUH/Taunton.

In set-up NBT/Yeovil

Mole Ix anaemia

UHB – Charlotte Bradbury/ Taunton